Carlton Hofferkamp & Jenks Wealth Management LLC Sells 1,199 Shares of Pfizer Inc. (NYSE:PFE)

Carlton Hofferkamp & Jenks Wealth Management LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,226 shares of the biopharmaceutical company’s stock after selling 1,199 shares during the quarter. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Pfizer were worth $817,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Tallon Kerry Patrick acquired a new position in Pfizer during the 4th quarter valued at approximately $509,000. Brighton Jones LLC raised its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Banque Pictet & Cie SA increased its stake in shares of Pfizer by 9.6% in the fourth quarter. Banque Pictet & Cie SA now owns 15,108 shares of the biopharmaceutical company’s stock worth $401,000 after acquiring an additional 1,318 shares during the period. Finally, TigerOak Management L.L.C. purchased a new position in shares of Pfizer during the fourth quarter worth $837,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Down 1.3%

Shares of NYSE:PFE opened at $24.51 on Monday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a market cap of $139.35 billion, a P/E ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57. The business has a fifty day moving average of $23.06 and a two-hundred day moving average of $24.95. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the firm posted $0.82 earnings per share. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.02%. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.